Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)

Jason D. Lickliter; Mark Voskoboynik; Linda Mileshkin; Hui K. Gan; Ganessan Kichenadasse; Kathy Zhang; Maggie Zhang; Zhiyu Tang; Michael Millward

doi:10.1038/s41416-021-01671-9

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)

Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward

College of Medicine and Public Health

Research output: Contribution to journal › Comment/debate

38 Downloads (Pure)

Abstract

The article “Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours”, written by Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward, was originally published electronically on the publisher’s internet portal on 18 November 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 2 December 2021 to

Original language	English
Article number	310
Pages (from-to)	310
Number of pages	1
Journal	British Journal of Cancer
Volume	126
Issue number	2
DOIs	https://doi.org/10.1038/s41416-021-01671-9
Publication status	Published - 1 Feb 2022

Keywords

phase 1A/1B
dose-escalation
pamiparib
Solid tumor
pharmacokinetics
antitumor activity
adverse events

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41416-021-01671-9Licence: CC BY

Published versionFinal published version, 245 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)'. Together they form a unique fingerprint.

Cite this

Lickliter, J. D., Voskoboynik, M., Mileshkin, L., Gan, H. K., Kichenadasse, G., Zhang, K., Zhang, M., Tang, Z., & Millward, M. (2022). Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2). British Journal of Cancer, 126(2), 310. Article 310. https://doi.org/10.1038/s41416-021-01671-9

Lickliter, Jason D. ; Voskoboynik, Mark ; Mileshkin, Linda et al. / Correction : Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2). In: British Journal of Cancer. 2022 ; Vol. 126, No. 2. pp. 310.

@article{93f75c5288eb4b8d96ba47a441d0b7ae,

title = "Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)",

abstract = "The article “Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours”, written by Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward, was originally published electronically on the publisher{\textquoteright}s internet portal on 18 November 2021 without open access. With the author(s){\textquoteright} decision to opt for Open Choice the copyright of the article changed on 2 December 2021 to",

keywords = "phase 1A/1B, dose-escalation, pamiparib, Solid tumor, pharmacokinetics, antitumor activity, adverse events",

author = "Lickliter, {Jason D.} and Mark Voskoboynik and Linda Mileshkin and Gan, {Hui K.} and Ganessan Kichenadasse and Kathy Zhang and Maggie Zhang and Zhiyu Tang and Michael Millward",

year = "2022",

month = feb,

day = "1",

doi = "10.1038/s41416-021-01671-9",

language = "English",

volume = "126",

pages = "310",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

Lickliter, JD, Voskoboynik, M, Mileshkin, L, Gan, HK, Kichenadasse, G, Zhang, K, Zhang, M, Tang, Z & Millward, M 2022, 'Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)', British Journal of Cancer, vol. 126, no. 2, 310, pp. 310. https://doi.org/10.1038/s41416-021-01671-9

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2). / Lickliter, Jason D.; Voskoboynik, Mark; Mileshkin, Linda et al.
In: British Journal of Cancer, Vol. 126, No. 2, 310, 01.02.2022, p. 310.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)

AU - Lickliter, Jason D.

AU - Voskoboynik, Mark

AU - Mileshkin, Linda

AU - Gan, Hui K.

AU - Kichenadasse, Ganessan

AU - Zhang, Kathy

AU - Zhang, Maggie

AU - Tang, Zhiyu

AU - Millward, Michael

PY - 2022/2/1

Y1 - 2022/2/1

N2 - The article “Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours”, written by Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward, was originally published electronically on the publisher’s internet portal on 18 November 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 2 December 2021 to

AB - The article “Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours”, written by Jason D. Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K. Gan, Ganessan Kichenadasse, Kathy Zhang, Maggie Zhang, Zhiyu Tang, Michael Millward, was originally published electronically on the publisher’s internet portal on 18 November 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 2 December 2021 to

KW - phase 1A/1B

KW - dose-escalation

KW - pamiparib

KW - Solid tumor

KW - pharmacokinetics

KW - antitumor activity

KW - adverse events

UR - http://www.scopus.com/inward/record.url?scp=85121560861&partnerID=8YFLogxK

U2 - 10.1038/s41416-021-01671-9

DO - 10.1038/s41416-021-01671-9

M3 - Comment/debate

AN - SCOPUS:85121560861

SN - 0007-0920

VL - 126

SP - 310

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

M1 - 310

ER -

Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K et al. Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2). British Journal of Cancer. 2022 Feb 1;126(2):310. 310. doi: 10.1038/s41416-021-01671-9

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (British Journal of Cancer, (2021), 10.1038/s41416-021-01632-2)

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this